OSU‐CLL cells transfected with CRISPR‐Cas9 and the TP53 guide RNA, but not treated with doxorubicin, were examined as a control for the transfection procedures involved. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.